ReviewCancers2017
Androgen Receptor Signaling in Bladder Cancer.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.Frontiers in oncology · 2021Pooled it
- Reproductive and hormonal factors and bladder cancer risk: a prospective study and meta-analysis.Aging · 2020Pooled it
- Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.Histology and histopathology · 2020Pooled it
- The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.Journal of advanced research · 2026Review
- Testosterone and cancers: biological functions, molecular mechanisms and therapy.Molecular cancer · 2026Review
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
- Machine-learning-based determination of sex-related bladder cancer biomarkers.bioRxiv : the preprint server for biology · 2025Article
- Testosterone and Androgen Receptor in Cancers with Significant Sex Dimorphism in Incidence Rates and Survival.Cancers · 2025Review
- Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.International journal of molecular sciences · 2025Review
- Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers, 2nd Edition.International journal of molecular sciences · 2025Article
- Metastasis development in non-muscle-invasive bladder cancer.Nature reviews. Urology · 2025Review
- Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach.Biomedicines · 2025Article
- Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study.BMC research notes · 2025Article
- Integrative multi-omics study identifies sex-specific molecular signatures and immune modulation in bladder cancer.Frontiers in bioinformatics · 2025Article
- Unveiling the Potential of S4 on Non-small Cell Lung Cancer Cells: Impact on Proliferation, Apoptosis, Senescence, and Metabolome Profile.Anti-cancer agents in medicinal chemistry · 2025Article
- Advancing personalized, predictive, and preventive medicine in bladder cancer: a multi-omics and machine learning approach for novel prognostic modeling, immune profiling, and therapeutic target discovery.Frontiers in immunology · 2025Article
- Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.BioData mining · 2024Article
- Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer.Biomedicines · 2024Article
- Sex-specific outcomes in cancer therapy: the central role of hormones.Frontiers in medical technology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging preclinical findings have indicated that steroid hormone receptor signaling plays an important role in bladder cancer outgrowth. In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer. This review summarizes and discusses the available data, suggesting the involvement of androgens and/or the androgen receptor pathways in urothelial carcinogenesis as well as tumor growth. While the precise mechanisms of the functions of the androgen receptor in urothelial cells remain far from being fully understood, current evidence may offer chemopreventive or therapeutic options, using androgen deprivation therapy, in patients with bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.